系統性研究肝X受體訊息調控血管新生與CD44調控攝護腺癌中歐洲紫杉醇抗藥性促進之轉移所扮演的角色

血管新生以及癌細胞轉移在腫瘤進程上都是不可或缺的，所以我們利用系統性的array去研究血管新生以及癌症轉移。我們之前的實驗結果指出肝X受體(LXR)參與了攝護腺癌細胞的增生。我們檢視了LXR在臍靜脈內皮細胞中的效應，LXR激活物T0901317會抑制臍靜脈的血管生成、移動能力以及降低雞胚胎的血管新生能力。而過度表現LXR標靶基因ApoD則會抑制血管的生成。此外ApoD與SR-B1存在著交換作用的關係，降低SR-B1的表現挽回了T0901317所抑制的臍靜脈內皮細胞的移動能力。而過度表現ApoD則抑制磷酸化eNOS、AKT、IL、MMP、VEGF、MCP1。我們的研究顯示活化LXR即活化了ApoD表現，進而抑制AKT/eNOS這條訊號傳遞路徑，抑制了一氧化氮的生成也抑制了血管新生。此外我們探討產生歐洲紫杉醇抗性攝護腺癌細胞有較高移動性與侵襲性的原因。我們利用MWA比較了由PC-3與DU-145衍生而來、具有歐洲紫杉醇抗性的PC/DX25與DU/DX50細胞以及其原始的PC-3、DU-145細胞蛋白質表現量差異。過度表現差異很大的ApoD與抑制表現ABCA1對於細胞移動能力無顯著影響。我們用流式細胞儀觀察另一個有顯著差異的蛋白CD44。PC/DX25與DU/DX50細胞存在著較高的CD44+子群。PC/DX25細胞表現較多的CD44、YAP、CYR61、CTGF、p-ERK1/2以及Vimentin蛋白。我們抑制表現CD44或YAP可有效抑制PC/DX25與DU/DX50的細胞移動能力。抑制CD44蛋白質會導致YAP、CYR61、CTGF、p-ERK1/2、p-AKT以及Vimentin表現的抑制，但增加了p-YAP S127的表現量。我們認為CD44蛋白表現量的提升可藉由Hippo-YAP這條路徑來促進歐洲紫杉醇抗藥性的 CRPC的細胞移動能力，而CD44/YAP這條路徑或許也能作為治療歐洲紫杉醇抗藥性的 CRPC的潛在標的。

關鍵字

血管新生；癌症轉移；肝X受體；攝護腺癌；歐洲紫杉醇

並列摘要

Angiogenesis and metastasis are essential for cancer progression. We discovered that treatment with liver X receptors (LXRs) agonist T0901317 inhibited the tube formation and migration of HUVECs as well as reduced the angiogenesis during embryogenesis of chicken eggs in vivo by CAM assay. Overexpression of LXR target gene ApoD suppressed the tube formation of HUVECs. Immunoprecipitation indicated that ApoD interacts with SR-B1, while knockdown of SR-B1 blocked inhibitory effects of T0901317 on HUVEC migration. T0901317 treatment or overexpression of ApoD decreased proteins expression level of phospho-eNOS S1177, phospho-Akt T308, phospho-Akt S473, eNOS, mTOR, VEGF-A, VEGF-C, IL-8, MMP-8, MMP-9, and MCP1. Our study demonstrated that activation of LXR retards angiogenesis through induction of LXR target gene ApoD, which in turn inhibits PI3K-Akt-eNOS signaling, an essential pathway for angiogenesis and production of nitric oxide. Additionally, we examined the molecular mechanism why docetaxel-resistant PC/DX25 and DU/DX50 cells derived from parental PC-3 and DU-145 PCa cells, respectively exhibited higher migration and invasion ability than parental cells. PC/DX25 cells highly expressed CD44, ABCA1 but lower ApoD as determined by Micro-Western Array (MWA), a high-throughput antibody-based proteomic platform, and Western blotting. Flow cytometry analysis demonstrated that PC/DX25 cells and DU/DX50 cells contain higher CD44+ population. MWA and Western blotting assay indicated that protein expression of CD44, YAP, CYR61, CTGF, phospho-ERK1/2 (T202/Y204), ERK and vimentin was elevated in PC/DX25 cells. Knockdown of CD44 or YAP inhibited migration and invasion of PC/DX25 and DU/DX50 cells. In addition, knockdown of CD44 reduced the expression of YAP, CTGF and CYR61 but increased phosphorylation of S127 on YAP. These observations suggested that CD44 promotes cell mobility of docetaxel-resistant PCa cells via induction of Hippo-Yap signaling pathway. CD44/YAP pathway may be a potential therapeutic target for docetaxel-resistant PCa metastasis.

並列關鍵字

Angiogenesis ； Metastasis ； Liver X receptor ； Prostate cancer ； Docetaxel

參考文獻

1. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nature reviews. Cancer 3, 401-410

Google Scholar

2. Black, W. C., and Welch, H. G. (1993) Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. The New England journal of medicine 328, 1237-1243

Google Scholar

3. Kerbel, R., and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nature reviews. Cancer 2, 727-739

Google Scholar

4. O'Reilly, M. S. (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exs 79, 273-294

Google Scholar

5. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285

Google Scholar

國際替代計量

系統性研究肝X受體訊息調控血管新生與CD44調控攝護腺癌中歐洲紫杉醇抗藥性促進之轉移所扮演的角色

全文下載

主題瀏覽